| Hatem Abed Asad, MD | |
|
30 Satellite Dr Ste 200, Winder, GA 30680-6211 | |
| (770) 586-0300 | |
| Not Available |
| Full Name | Hatem Abed Asad |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 37 Years |
| Location | 30 Satellite Dr Ste 200, Winder, Georgia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1326095662 | NPI | - | NPPES |
| 504882696A | Medicaid | GA |
| Facility Name | Location | Facility Type |
|---|---|---|
| Houston Medical Center | Warner robins, GA | Hospital |
| Mercy Hospital | Iowa city, IA | Hospital |
| Northside Hospital | Atlanta, GA | Hospital |
| Entity Name | Pulmonary Associates, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1730199662 PECOS PAC ID: 5890754113 Enrollment ID: O20041004000477 |
News Archive
AVANIR Pharmaceuticals, Inc. today announced that NUEDEXTA™ (dextromethorphan hydrobromide and quinidine sulfate) is now available by prescription in the United States. NUEDEXTA is the first and only treatment approved by the U.S. Food and Drug Administration (FDA) for pseudobulbar affect (PBA).
Some of us can hold our tongues better than others but even the best of us will blurt out the truth when we're tired, stressed or distracted, according to a new research report.
Domain Therapeutics, a biopharmaceutical company that specializes in the discovery and development of G protein-coupled receptor (GPCR) drugs, today announces the creation of Mavalon Therapeutics, a company focused on stopping the progression of Parkinson's disease.
By applying a systems biology approach, a recent bioRxiv* preprint research paper by scientists from the Icahn School of Medicine at Mount Sinai in New York unveils interactions between the severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) and p38 mitogen-activated protein kinase (MAPK) pathway responsible for regulating the expression of crucial inflammatory mediators in human lung epithelial cells.
› Verified 9 days ago
| Entity Name | Northside Primary Care Professional Services,llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1922397553 PECOS PAC ID: 9638343924 Enrollment ID: O20111123000206 |
News Archive
AVANIR Pharmaceuticals, Inc. today announced that NUEDEXTA™ (dextromethorphan hydrobromide and quinidine sulfate) is now available by prescription in the United States. NUEDEXTA is the first and only treatment approved by the U.S. Food and Drug Administration (FDA) for pseudobulbar affect (PBA).
Some of us can hold our tongues better than others but even the best of us will blurt out the truth when we're tired, stressed or distracted, according to a new research report.
Domain Therapeutics, a biopharmaceutical company that specializes in the discovery and development of G protein-coupled receptor (GPCR) drugs, today announces the creation of Mavalon Therapeutics, a company focused on stopping the progression of Parkinson's disease.
By applying a systems biology approach, a recent bioRxiv* preprint research paper by scientists from the Icahn School of Medicine at Mount Sinai in New York unveils interactions between the severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) and p38 mitogen-activated protein kinase (MAPK) pathway responsible for regulating the expression of crucial inflammatory mediators in human lung epithelial cells.
› Verified 9 days ago
| Entity Name | Chronic Disease Management Of Georgia Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1699300939 PECOS PAC ID: 7618306721 Enrollment ID: O20200409003695 |
News Archive
AVANIR Pharmaceuticals, Inc. today announced that NUEDEXTA™ (dextromethorphan hydrobromide and quinidine sulfate) is now available by prescription in the United States. NUEDEXTA is the first and only treatment approved by the U.S. Food and Drug Administration (FDA) for pseudobulbar affect (PBA).
Some of us can hold our tongues better than others but even the best of us will blurt out the truth when we're tired, stressed or distracted, according to a new research report.
Domain Therapeutics, a biopharmaceutical company that specializes in the discovery and development of G protein-coupled receptor (GPCR) drugs, today announces the creation of Mavalon Therapeutics, a company focused on stopping the progression of Parkinson's disease.
By applying a systems biology approach, a recent bioRxiv* preprint research paper by scientists from the Icahn School of Medicine at Mount Sinai in New York unveils interactions between the severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) and p38 mitogen-activated protein kinase (MAPK) pathway responsible for regulating the expression of crucial inflammatory mediators in human lung epithelial cells.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Hatem Abed Asad, MD 30 Satellite Dr Ste 200, Winder, GA 30680-6211 Ph: (770) 586-0300 | Hatem Abed Asad, MD 30 Satellite Dr Ste 200, Winder, GA 30680-6211 Ph: (770) 586-0300 |
News Archive
AVANIR Pharmaceuticals, Inc. today announced that NUEDEXTA™ (dextromethorphan hydrobromide and quinidine sulfate) is now available by prescription in the United States. NUEDEXTA is the first and only treatment approved by the U.S. Food and Drug Administration (FDA) for pseudobulbar affect (PBA).
Some of us can hold our tongues better than others but even the best of us will blurt out the truth when we're tired, stressed or distracted, according to a new research report.
Domain Therapeutics, a biopharmaceutical company that specializes in the discovery and development of G protein-coupled receptor (GPCR) drugs, today announces the creation of Mavalon Therapeutics, a company focused on stopping the progression of Parkinson's disease.
By applying a systems biology approach, a recent bioRxiv* preprint research paper by scientists from the Icahn School of Medicine at Mount Sinai in New York unveils interactions between the severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) and p38 mitogen-activated protein kinase (MAPK) pathway responsible for regulating the expression of crucial inflammatory mediators in human lung epithelial cells.
› Verified 9 days ago
Waheed Ahmad Bhatti, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 133 W Athens St, Winder, GA 30680 Phone: 770-867-6633 | |
Malik M Malik, MBBS Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 30 Satellite Dr Ste 200, Winder, GA 30680 Phone: 770-586-0300 | |
Dr. Derrick Eugene Sims, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 316 N Broad St, Winder, GA 30680 Phone: 770-307-5400 | |
Wayne Dwight Austin, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 260 N Broad St, Winder, GA 30680 Phone: 770-867-9800 Fax: 770-868-4569 | |
Mrs. Aja S. Mccutchen, M.D Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 299 N Broad St, Winder, GA 30680 Phone: 678-987-1480 Fax: 678-987-1481 | |
Rasha Al Samara, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 30 Satellite Dr, Ste 100, Winder, GA 30680 Phone: 770-586-0310 Fax: 770-586-0312 |